Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis: Multicenter, Open-Label, Randomized Controlled Trial

NCT07550673 is registered in ClinicalTrials.gov with Xijing Hospital of Digestive Diseases as lead sponsor.

NCT NCT07550673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07550673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis: Multicenter, Open-Label, Randomized Controlled Trial
Lead sponsor
Xijing Hospital of Digestive Diseases
Phase
Phase 4
Overall status
Recruiting
Start date
April 20, 2026
Completion date
November 1, 2028
Enrollment
226 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute severe ulcerative colitis